Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study

NCT07877272 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT07877272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Endohepatology-Based Reclassification of Treatment Indication in High-Risk Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective, Multicenter Observational Study
Lead sponsor
University Hospital Muenster
Phase
Observational
Overall status
Recruiting
Start date
October 5, 2026
Completion date
April 1, 2030
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibrosis, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, portal hypertension